Tango combination produces 82% response rate in advanced pancreatic cancer trial
Tango Therapeutics reported that its experimental drug, used with Revolution Medicines’ Rasonque, produced tumor responses in 82% of patients with a particular form of advanced pancreatic cancer. The clinical trial findings, presented Friday in Madrid, also suggested that the benefit persisted: nine months after treatment, 88% of participants were alive and had experienced no tumor progression.
The results provide early support for combining targeted medicines in pancreatic cancer, rather than relying on a single targeted drug. The regimen is especially notable because it does not include chemotherapy, which has long been a standard treatment for this aggressive disease and can impose a substantial burden on patients.
The available report does not identify the precise pancreatic cancer subtype, the Tango drug, the number of patients enrolled, or the trial phase. Those omissions limit how broadly the findings can be interpreted, and the response and nine-month progression-free survival figures do not by themselves establish longer-term survival or superiority to current care. Even so, the high response rate and apparent durability make the chemotherapy-free combination an encouraging approach for the selected patient group studied.
Continue in the app — vote & join in ➔